by Alicia Gailliez, Business Development Manager, One Nucleus

Community drives motivation, which helps to create action.
You can see this reflected in the energy, insights, and calls to action that arise from ON Helix. Long after the day of the event itself, as follow-up discussions continue via the conference app, new connections continue to be built exploring opportunities for collaboration as key takeaway messages emerge.
Advancing innovative medicines to patients requires a community that brings together researchers sharing their knowledge, start-ups meeting potential partners, investors discovering innovative technologies, and voices that can bring real-world patient perspectives into the conversation.
Creating the conditions for that to happen is at the heart of what One Nucleus aims to achieve.
Whether you attend as a delegate, sponsor or exhibitor, ON Helix provides a platform for connection and an environment that encourages genuine relationship building rather than transactional networking.
ON Helix plays three important roles in strengthening our innovation ecosystem:
ON Helix Connects
It brings together people from across the life sciences community. When biotech founders, academic institutes, investors, contract research and development organisations and professional service providers are all in one place, it creates opportunities for meaningful conversations, relationship-building and future collaborations.
ON Helix Inspires
Through keynotes, panel discussions and company presentations, ON Helix spotlights what’s next for life sciences. Together with conversations sparked during the networking, it provides an opportunity to learn from others, challenge existing thinking, and gain fresh insights into where our industry is heading.
ON Helix Enables
ON Helix helps turn conversations into action by creating an environment for ideas to emerge.
At ON Helix 2026 attendees will gain valuable insights into some of the most important topics disrupting bio innovation today. This year's themes will explore areas including RNA therapeutics, AI and computational platforms, innovation in clinical trials, and how we can build stronger global bio-innovation ecosystems.